

# CytRx to Hold Town Hall for Stockholders on Thursday, January 20<sup>th</sup>

*Town Hall to be Led by New CEO Dr. Stephen Snowdy*

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it will hold a town hall for stockholders on Thursday, January 20, 2022 at 4:30 PM Eastern. The town hall will be led by the Company’s Chief Executive Officer, Dr. Stephen Snowdy, and include a question-and-answer session. The town hall can be accessed [here](#).

A recording of the town hall will be available on CytRx's website under the News & Events section following the event.

## **About CytRx**

CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in two indications, including Niemann-Pick disease Type C (NPC), and Gaucher disease. CytRx Corporation’s website is [www.cytrx.com](http://www.cytrx.com).

## **Contacts**

Longacre Square Partners  
Greg Marose / Bela Kirpalani  
[cytrx@longacresquare.com](mailto:cytrx@longacresquare.com)

###